Full Text View
Tabular View
No Study Results Posted
Related Studies
Raloxifene and Rimostil for Perimenopause-Related Depression
This study is currently recruiting participants.
Verified September 2012 by National Institutes of Health Clinical Center (CC)
Study NCT00030147   Information provided by National Institutes of Health Clinical Center (CC)

First Received on February 6, 2002.   Last Updated on May 1, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Perimenopausal Depression
Depression
Additional conditions recognized in this trial
Depressive Disorder
More general conditions related to this trial
Behavioral Symptoms
Mental Disorders
Mood Disorders
Interventions listed in this trial
Raloxefine (Evista)
Rimostil
Evista, Rimostil, Alora
Additional drug interventions recognized in this trial
Estrogen Receptor Modulators
Estrogens
Raloxifene
Selective Estrogen Receptor Modulators
More general drug interventions related to this trial
Bone Density Conservation Agents
Estrogen Antagonists
Hormone Antagonists
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
National Institute of Mental Health (NIMH)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services